2-Allyloxy-fluorenon | 57248-10-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 2-Allyloxy-fluorenon
• 英文别名: 2-allyloxy-fluoren-9-one；2-Allyloxy-fluoren-9-on；2-Prop-2-enoxyfluoren-9-one
• CAS: 57248-10-9
• 化学式: C₁₆H₁₂O₂
• 分子量: 236.27
• InChiKey: ASPLQHATFDOWEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Allyloxy-fluorenon 生成 2-Hydroxy-1-allyl-fluorenon
  参考文献：
  名称：

  THOMAS T. C.; SETHNA S., J. INDIAN CHEM. SOC. , 1975, 52, NO 7, 609-613

  摘要：

  DOI：
• 作为产物：
  描述：

  2-羟基-9-芴 、 3-溴丙烯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-Allyloxy-fluorenon
  参考文献：
  名称：

  [EN] MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS
  [FR] INHIBITEURS MACROCYCLIQUES, DE TYPE OXIMYLE, DES PROTÉASES À SÉRINE DU VIRUS DE L'HÉPATITE C

  摘要：

  本发明涉及式(I)化合物，或其药用可接受的盐、酯或前药：其抑制丝氨酸蛋白酶活性，尤其是丙型肝炎病毒(HCV) NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还可用作抗病毒剂。本发明进一步涉及包含前述化合物的药物组合物，用于给患有HCV感染的对象服用。本发明还涉及通过管理包含本发明化合物的药物组合物来治疗主体中的HCV感染的方法。

  公开号：

  WO2009079352A1

文献信息

• [EN] MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS MACROCYCLIQUES, DE TYPE OXIMYLE, DES PROTÉASES À SÉRINE DU VIRUS DE L'HÉPATITE C
  申请人：ENANTA PHARM INC

  公开号：WO2009079352A1

  公开（公告）日：2009-06-25

  The present invention relates to compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

  本发明涉及式(I)化合物，或其药用可接受的盐、酯或前药：其抑制丝氨酸蛋白酶活性，尤其是丙型肝炎病毒(HCV) NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还可用作抗病毒剂。本发明进一步涉及包含前述化合物的药物组合物，用于给患有HCV感染的对象服用。本发明还涉及通过管理包含本发明化合物的药物组合物来治疗主体中的HCV感染的方法。
• Remarks on the Structure of Fluorene
  作者：Ernst Bergmann、T. Berlin

  DOI：10.1021/ja01859a021

  日期：1940.2
• MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20090180984A1

  公开（公告）日：2009-07-16

  The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
• FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
  申请人：Gai Yonghua

  公开号：US20090238794A1

  公开（公告）日：2009-09-24

  The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US8222203B2
  申请人：——

  公开号：US8222203B2

  公开（公告）日：2012-07-17